Back to compounds

COMPOUND PROFILE / SMALL MOLECULES

CT-996.

Research draft

CT-996 is an experimental oral non-peptide GLP-1 receptor agonist.

Keep the context.

Research evidence and COA results do not establish suitability for use. This is educational information, not a dosing guide or personal medical advice.

Targeted source and identity review, not a systematic review or complete regulatory audit.

Overview

CT-996 is an experimental oral non-peptide GLP-1 receptor agonist.

CLASSIFICATIONSmall molecules
MOLECULAR / SEQUENCE INFONot specified
PRIMARY CONTEXTCompound

Mechanism

It targets GLP-1 signalling through a small molecule.

Human research

The developer reported early phase 1 weight-loss findings. Sponsor announcements are not equivalent to a full independently assessed publication.

Preclinical & other research

Preclinical receptor and metabolic studies informed development.

Safety & unknowns

Early tolerability and limited participant exposure cannot settle long-term safety.

Regulatory status

Investigational; clinical-program status is time-sensitive.

Reported use & evidence

Research profile draft

The supplied CT-996 profile and its cited sources are imported. Community experiences and laboratory evidence remain separate from these descriptions. Missing evidence is not a zero result.

Sources & references

Follow the cited records and registered research. Profiles remain research drafts.

Explore more compounds